BioNTech Other Liab from 2010 to 2024
| BNTX Stock | USD 98.24 0.26 0.27% |
Other Liabilities | First Reported 2010-12-31 | Previous Quarter 326.5 M | Current Value 166.9 M | Quarterly Volatility 124 M |
Check BioNTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNTech's main balance sheet or income statement drivers, such as Tax Provision of 243 M, Net Interest Income of 367.2 M or Interest Income of 375.5 M, as well as many indicators such as Price To Sales Ratio of 5.71, Dividend Yield of 0.0113 or PTB Ratio of 1.19. BioNTech financial statements analysis is a perfect complement when working with BioNTech Valuation or Volatility modules.
BioNTech | Other Liab |
Latest BioNTech's Other Liab Growth Pattern
Below is the plot of the Other Liab of BioNTech SE over the last few years. It is BioNTech's Other Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioNTech's overall financial position and show how it may be relating to other accounts over time.
| Other Liab | 10 Years Trend |
|
Other Liab |
| Timeline |
BioNTech Other Liab Regression Statistics
| Arithmetic Mean | 112,512,383 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 110.23 | |
| Mean Deviation | 107,438,593 | |
| Median | 97,109,000 | |
| Standard Deviation | 124,018,367 | |
| Sample Variance | 15380.6T | |
| Range | 326.5M | |
| R-Value | 0.83 | |
| Mean Square Error | 5271T | |
| R-Squared | 0.68 | |
| Significance | 0.0001 | |
| Slope | 22,897,694 | |
| Total Sum of Squares | 215327.8T |
BioNTech Other Liab History
About BioNTech Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include BioNTech income statement, its balance sheet, and the statement of cash flows. BioNTech investors use historical funamental indicators, such as BioNTech's Other Liab, to determine how well the company is positioned to perform in the future. Although BioNTech investors may use each financial statement separately, they are all related. The changes in BioNTech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on BioNTech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on BioNTech Financial Statements. Understanding these patterns can help to make the right decision on long term investment in BioNTech. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Other Liabilities | 326.5 M | 166.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.